2021 PTAB Year in Review: Analysis & Trends: Biologics at th

In June 2021, the US Patent and Trademark Office (USPTO) published an update to its study of America Invents Act (AIA) trials involving challenges to Orange Book-listed and biologic...

Related Keywords

Delaware , United States , America , Adello Biologics , Sanofi Aventis Deutschland Gmb , Goldstein Fox , Coherus Biosciences , Fresenius Kabi , Genentech Avastin , Amgen , Genentech , Coherus Biosciences Inc , Institution Decision , Biogen Inc , Celltrion Inc , Pfizer , Trademark Office , Pfizer Inc , See Adello Biologics , Pilot Program , Tanvex Biopharma United States Inc , Mylan Inc , Fresenius Kabi United States , Genentech Inc , Tox Inc , Inst Inc , Fresenius , Pilot Program Concerning Motion To Amend Practice , Hospira Inc , Amgen Inc , Mylan Pharmaceuticals Inc , America Invents Act , Orange Book Listed , Orange Book , Appeal Board , Patent Owners , Rituxan Label , Office Manager , Internet Archives , Patent Owner , Federal Circuit , Botulinum Toxin Galderma , Program Concerning Motion , Amend Practice , Preliminary Guidance , Lupin Limited , Tanvex Biopharma United States , Accord Biopharma , Insulin Glargine , Mylan Pharmaceuticals , Aventis Deutschland Gmbh , Kabi United States , Biopharma United States , Sanofi Aventis Deutschland Gmbh ,